Drug Approval | February 23, 2022
Zydus receives USFDA approval for Dapagliflozin tablets
The drug will be manufactured at the group's formulation manufacturing facility at the SEZ, Ahmedabad
The drug will be manufactured at the group's formulation manufacturing facility at the SEZ, Ahmedabad
Four additional AT2R agonists are expected to finalize preclinical evaluation during 2022
Collaboration aims to evolve precision medicine with cell-specific delivery of gene therapy
A National Tele Mental Health Programme is being launched to address mental health issues. We spoke to healthcare industry leaders who shared their outlook
Oral semaglutide is a co-formulation of GLP-1RA semaglutide with an absorption enhancer SNAC which protects semaglutide from undergoing degradation in the stomach
Despite the challenges of pandemic disruptions, drug developers advance promising therapies for conditions, including Alzheimer's, diabetes and asthma
Decisions reaffirm the ability of Biocon Biologics and Viatris to provide patient access to interchangeable Semglee
Sputnik Light as a booster significantly increases virus-neutralizing activity against Omicron based on sera 2-3 months after revaccination and is a universal booster to other vaccines inducing stronger antibody and T-cell response
Sputnik M is a new member of the Sputnik vaccines family
The investigational compound, GZR18, is a novel analogue of glucagon-like peptide-1 (GLP-1), an incretin hormone responsible for many glucoregulatory effects
Subscribe To Our Newsletter & Stay Updated
